Twist Bioscience Corp
For the period ended Dec 31, 2024. Filed Feb 3, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 3, 2025
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
| (In thousands except per share data) | December 31,2024 | September 30,2024 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $221,403 | $226,316 |
| Short-term investments | 49,424 | 50,083 |
| Accounts receivable, net | 39,315 | 34,903 |
| Inventories | 23,518 | 24,078 |
| Prepaid expenses and other current assets | 11,649 | 11,396 |
| Total current assets | $345,309 | $346,776 |
| Property and equipment, net | 100,669 | 102,520 |
| Operating lease right-of-use assets | 56,475 | 58,829 |
| Goodwill | 85,811 | 85,811 |
| Intangible assets, net | 14,215 | 14,478 |
| Restricted cash, non-current | 2,656 | 2,816 |
| Other non-current assets | 3,445 | 3,093 |
| Total assets | $608,580 | $614,323 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $7,503 | $1,630 |
| Accrued expenses | 20,129 | 15,104 |
| Accrued compensation | 21,742 | 33,650 |
| Current portion of operating lease liability | 15,030 | 14,805 |
| Other current liabilities | 5,242 | 5,817 |
| Total current liabilities | $69,646 | $71,006 |
| Operating lease liability, net of current portion | 67,586 | 70,221 |
| Liability related to the sale of future revenue | 15,000 | — |
| Other non-current liabilities | 407 | 407 |
| Total liabilities | $152,639 | $141,634 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, $0.00001 par value —100,000 and 100,000 shares authorized at December 31, 2024 and September 30, 2024, respectively; 59,582 and 58,877 shares issued and outstanding at December 31, 2024 and September 30, 2024, respectively | $— | $— |
| Additional paid-in capital | 1,730,092 | 1,715,119 |
| Accumulated other comprehensive income/(loss) | (649) | (522) |
| Accumulated deficit | (1,273,502) | (1,241,908) |
| Total stockholders’ equity | $455,941 | $472,689 |
| Total liabilities and stockholders’ equity | $608,580 | $614,323 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.